SyndromeX

Company Overview

Snapshot

Founded in July 2008 by Jacob Bar-Tana, SyndromeX operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing a single drug for the treatment of metabolic syndrome, a technology success story initiated in July 2008.

Business overview

SyndromeX is a pharmaceutical company specializing in the development of drugs for metabolic syndrome and related conditions such as dyslipidemia, type-2 diabetes, obesity, hypertension, and atherosclerotic cardiovascular disease. The company's core technology aims to provide an all-in-one therapy, reducing the need for multiple medications. SyndromeX operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals market with a B2B business model.

Company Intelligence Q&A

What is SyndromeX's primary focus?

SyndromeX is a pharmaceutical company focused on developing drugs for metabolic syndrome and associated diseases like dyslipidemia, type-2 diabetes, obesity, hypertension, and atherosclerotic cardiovascular disease.

When was SyndromeX founded?

SyndromeX was founded in July 2008.

Who is the founder of SyndromeX?

Jacob Bar-Tana, MD, Ph.D. is the founder of SyndromeX.

What is SyndromeX's strategic goal regarding metabolic syndrome treatment?

SyndromeX aims to develop an all-in-one therapy for metabolic syndrome and its component diseases, intending to simplify treatment for patients who typically take multiple drugs.

In which sector does SyndromeX primarily operate?

SyndromeX operates within the Health Tech & Life Sciences sector, specifically focusing on Pharmaceuticals.